Yanan Zhu
Stock Analyst at Wells Fargo
(2.19)
# 2,828
Out of 5,154 analysts
82
Total ratings
36.84%
Success rate
-0.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $12 → $15 | $13.44 | +11.61% | 8 | Mar 3, 2026 | |
| QURE uniQure | Downgrades: Equal-Weight | $60 → $15 | $14.27 | +5.12% | 6 | Mar 3, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $45 → $38 | $16.71 | +127.41% | 8 | Feb 27, 2026 | |
| ACLX Arcellx | Downgrades: Equal-Weight | $115 | $114.33 | +0.59% | 1 | Feb 23, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Overweight | $40 → $50 | $40.15 | +24.53% | 3 | Feb 20, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $8 → $11 | $4.57 | +140.70% | 4 | Jan 5, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $82 → $100 | $74.04 | +35.06% | 4 | Jan 5, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $7.11 | +181.29% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.00 | +100.00% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $29.86 | +50.70% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $1.48 | +710.81% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $1.33 | +87.97% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.51 | +231.13% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $5.13 | +172.90% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $26.54 | +163.75% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.90 | +156.41% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $56.50 | +15.04% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.68 | +245.62% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.38 | +959.60% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $3.61 | +12,365.37% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $717.79 | -54.58% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $79 → $70 | $10.16 | +588.98% | 2 | Oct 29, 2020 |
Intellia Therapeutics
Mar 3, 2026
Maintains: Equal-Weight
Price Target: $12 → $15
Current: $13.44
Upside: +11.61%
uniQure
Mar 3, 2026
Downgrades: Equal-Weight
Price Target: $60 → $15
Current: $14.27
Upside: +5.12%
Sarepta Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $45 → $38
Current: $16.71
Upside: +127.41%
Arcellx
Feb 23, 2026
Downgrades: Equal-Weight
Price Target: $115
Current: $114.33
Upside: +0.59%
Spyre Therapeutics
Feb 20, 2026
Maintains: Overweight
Price Target: $40 → $50
Current: $40.15
Upside: +24.53%
Taysha Gene Therapies
Jan 5, 2026
Maintains: Overweight
Price Target: $8 → $11
Current: $4.57
Upside: +140.70%
Ionis Pharmaceuticals
Jan 5, 2026
Maintains: Overweight
Price Target: $82 → $100
Current: $74.04
Upside: +35.06%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $7.11
Upside: +181.29%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.00
Upside: +100.00%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $29.86
Upside: +50.70%
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.48
Upside: +710.81%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.33
Upside: +87.97%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.51
Upside: +231.13%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $5.13
Upside: +172.90%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $26.54
Upside: +163.75%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.90
Upside: +156.41%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $56.50
Upside: +15.04%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $8.68
Upside: +245.62%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.38
Upside: +959.60%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $3.61
Upside: +12,365.37%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $717.79
Upside: -54.58%
Oct 29, 2020
Maintains: Overweight
Price Target: $79 → $70
Current: $10.16
Upside: +588.98%